Ritter Pharmaceuticals Inc. (Nasdaq: RTTR) reported upbeat results from a Phase 2b/3 study of its lactose intolerance treatment RP-G28 but the stock price fell 35 cents to close at $1.60.
Upbeat results for Ritter Pharmaceuticals
March 29, 2017 at 18:16 PM EDT
